

Current Primary Care Prescribing Rebate Schemes (21/22)

Name of scheme:	Drug(s) / Device(s) covered	Company involved in the scheme	Start date of agreement	End date of agreement
Apidra insulin	All products	Sanofi	01.07.2021	30.06.2022
Insuman insulin	All products	Sanofi	01.07.2021	30.06.2022
Toujeo insulin	All products	Sanofi	01.04.2020	31.03.2022
Biquelle XL	All strengths	Aspire	01.07.2021	30.06.2023
Clenil Modulite CFC free inhaler	All strengths	Chiesi	01.07.2021	30.06.2023
Fostair NEXThaler dry powder inhaler	Both strengths	Chiesi	01.05.2021	30.04.2023
Fostair pressurised metered dose inhaler	Both strengths	Chiesi	01.08.2021	31.07.2023
Edoxaban (Lixiana)	All strengths	Daiichi Sankyo	01.01.2018	31.12.2024
Gatalin XL	All strengths	Aspire	01.09.2021	31.08.2023
Prostap DCS	Both strengths	Takeda	01.06.2014	Upon termination by either party
Rivaroxaban (Xarelto)	Tablets 10mg, 15mg & 20mg	Bayer	01.10.2020	To be terminated 31.12.2021
Sirdupla inhaler	125mcg strength only	Mylan	01.01.2021	31.12.2021 (under review)
Longtec MR	All strengths	Qdem	01.01.2020	Upon termination by either party
FreeStyle Libre	FreeStyle Libre & Freestyle Libre 2	Abbott	01.08.2021	31.07.2022

Correct as of 29.12.2021

Please note, if a scheme is showing as expired, it may currently be under review and not yet been approved internally or have a signed agreement in place. Upon commencement of a rebate agreement, this page will be updated accordingly.